Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9 ...

Aortic valve narrowing (aortic stenosis) with concomitant cardiac amyloidosis is a severe heart disease of old age that is ...

The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

Four blue-chip stocks are trading near their 52-week lows and offering investors incredible entry points and huge dividends.

A new portable device developed by Rutgers University researchers can detect genetic mutations linked to hereditary ...

Many artists at any age simply cannot live without a stage. But after 70 years it is already very difficult to work, said ...